Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 20/20 | 1.00 |
| ▸ | F2 | P00734 | 17/20 | 1.00 |
| ▸ | F9 | P00740 | 2/20 | 0.84 |
| ▸ | CTRB1 | P17538 | 2/20 | 0.84 |
| ▸ | F5 | P12259 | 1/20 | 0.84 |
| ▸ | PROC | P04070 | 1/20 | 0.83 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6197266 | 0.94 | F10 (1.00) | F10F2F9CTRB1F5 | |
| SCHEMBL5376245 | 0.93 | F10 (1.00) | F10F2F9CTRB1F5 | |
| SCHEMBL6503086 | 0.93 | F10 (1.00) | F10F2F9CTRB1F5 | |
| Razaxaban SCHEMBL29376499 | 0.91 | F10 (1.00) | F10F2F9CTRB1F5 | |
| Razaxaban SCHEMBL677372 | 0.91 | F10 (1.00) | F10F2F9CTRB1F5 | |
| Razaxaban SCHEMBL29456625 | 0.91 | F10 (1.00) | F10F2F9CTRB1F5 | |
| Razaxaban SCHEMBL6885838 | 0.91 | F10 (1.00) | F10F2F9CTRB1F5 | |
| SCHEMBL12589578 | 0.90 | F10 (1.00) | F10F2F9CTRB1F5 | |
| SCHEMBL5384478 | 0.90 | F10 (1.00) | F10F2F9CTRB1F5 | |
| SCHEMBL6493125 | 0.90 | F10 (0.88) | F10F2F9CTRB1F5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1460996-A4 | NOVEL-N-4-(1H-IMIDAZOL-1-YL)-2-FLUOROPHENYL]-3-(TRIFLUOROMETHYL)-1-H-PYRAZOLE-5-CARBOXAMIDES AS FACTOR XA | BRISTOL MYERS SQUIBB CO (US) | 2005-11-16 | — | — | EP | disclosed |
| EP-1460996-A2 | NOVEL-N-4-(1H-IMIDAZOL-1-YL)-2-FLUOROPHENYL]-3-(TRIFLUOROMETHYL)-1-H-PYRAZOLE-5-CARBOXAMIDES AS FACTOR XA | Bristol-Myers Squibb Company (US) | 2004-09-29 | — | — | EP | disclosed |
| US-6730689-B2 | HETEROCYCLIC AMIDES SUCH AS N-(4-(2-(((METHYL)AMINO)METHYL)-1H-IMIDAZOL-1-YL)-2-FLUOROPHENYL)-1-(3-AMINO-1,2-BENZISOXAZOL-5-YL)-3-(TRIFLUOROMETHYL)-1H-PYRAZOLE-5-CARBOXAMIDE, USED AS ANTICOAGULANTS; PROPHYLAXIS OF CARDIOVASCULAR DISORDERS | BRISTOL-MYERS SQUIBB COMPANY | 2004-05-04 | — | — | US | disclosed |
| US-20030144287-A1 | Novel N-[4- (1H-imidazol-1-yl) -2-fluorophenyl ] -3- (trifluoromethyl) -1H-pyrazole-5-carboxamides as factor Xa inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2003-07-31 | — | — | US | disclosed |
| WO-2003047517-A2 | NOVEL-N-[4-(1H-IMIDAZOL-1-YL)-2-FLUOROPHENYL]-3-(TRIFLUOROMETHYL)-1-H-PYRAZOLE-5-CARBOXAMIDES AS FACTOR XA | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-06-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030144287-A1 | Novel N-[4- (1H-imidazol-1-yl) -2-fluorophenyl ] -3- (trifluoromethyl) -1H-pyrazole-5-carboxamides as factor Xa inhibitors | F11, SERPINC1, TFPI | F10 8/4885F2 9/4885F9 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.